SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the topline results from the LIGHTSITE ...
A Recently Completed Dry Eye Disease Field Trial, which Was Numerically Supportive of Reproxalap and Consistent with Prior Field Trials, Did Not Reach Statistical Significance, and Is Expected to be ...
LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce ...
BEIJING, Aug. 3, 2025 /PRNewswire/ -- Raytone Biotech, a clinical-stage biotechnology company dedicated to innovative ophthalmic therapies, announced that it successfully completed the first patient ...
PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611, targeting dry age-related macular degeneration (AMD) and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback